Articles

Poll

Podcasts

Slideshows

Videos

Hematology

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

Hematology Month in Review: June 2025

Novartis has announced the safety and efficacy of iptacopan, a twice-daily oral monotherapy for adult patients who switched from eculizumab or ravulizumab.

Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

Hematology Month in Review: May 2025

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.

Ruxoprubart Shows Efficacy for PNH in Interim Phase 2 Trial Results

Paroxysmal Nocturnal Hemoglobinuria Condition Center page, visitors can find resources on the topics of medical news and expert insight into PNH. Content includes articles, interviews, videos, podcasts, and breaking news on PNH research, treatment, and drug development.